Immediate-release tablet of Active X, 100 mg
Development objective: robust oral tablet prototype with rapid dissolution, acceptable content uniformity, adequate hardness/friability performance and a manufacturing process that can be scaled without hidden sensitivity.
Formulation Development Bench
Target mass set
Prototype Selection Board
Prototype A — Direct Compression
High MCC + superdisintegrant. Simple process, but API flow remains the dominant risk.
Fast processFlow riskCU sensitivityPrototype B — Dry Granulation
Improved flow and content-uniformity potential without exposing the moisture-sensitive API to water.
Better flowMoisture compatibleCompaction historyPrototype C — Wet Granulation
Excellent flow and tablet appearance, but moisture exposure creates a significant API stability concern.
Excellent flowStrong tabletsMoisture riskPrototype Dissolution Comparison
| Prototype | 15 min | 30 min | Profile note |
|---|---|---|---|
| A | 72% | 88% | Acceptable but slower than B |
| B | 84% | 96% | Fast, consistent release |
| C | 61% | 84% | Slower release after wet granulation |
Manufacturability Review
| Attribute | A | B | C |
|---|---|---|---|
| Blend flow | Borderline | Good | Very good |
| Content uniformity risk | Moderate | Low | Low |
| Tablet hardness | 7.1 kp | 7.8 kp | 9.0 kp |
| Friability | 0.72% | 0.48% | 0.35% |
| Moisture exposure | Low | Low | High |
| Process complexity | Low | Medium | Medium-high |
Scale-Up Risk Review
Poor API flow increases risk that blend uniformity at lab scale will not translate cleanly to larger equipment.
Roll force and resulting granule density may affect tabletability and dissolution if not controlled during scale-up.
Water exposure and drying history may affect API stability and granule properties.
Over-lubrication can weaken tablets or slow dissolution; blending time should remain a controlled development variable.